The therapy allows to intervene on patients who cannot undergo bypass or angioplasty
AOSTA. An innovative interventional cardiological treatment called Reducer was used for the first time at the U. Parini regional hospital. This was announced by the USL company explaining that the treatment is aimed at “highly complex” patients who suffer from severe coronary artery disease and who cannot undergo traditional interventions such as bypass or angioplasty. The beneficiary was a Valle d’Aosta patient suffering from “severely symptomatic and non-revascularized critical multivessel coronary artery disease”.
The head of Cardiology, Paolo Scacciatella, explains: “Every year, between 1 and 5% of patients with ischemic heart disease undergoing coronary angiography have coronary artery disease so severe and extensive that it cannot be treated. disabling forms of angina pectoris and are forced to frequent hospitalization, are defined as “no-option”, ie without therapeutic options. This interventional therapy consists in the placement through the right jugular vein of an occluding stent in the coronary venous sinus and is aimed at increasing the perfusion of the microcirculation of the ischemic heart with consequent improvement of anginal symptoms and functional capacity “.
“The Reducer system – specifies the health company – is considered in the European Guidelines for patients with refractory angina pectoris (2019 European Society of Cardiology Guidelines for the diagnosis and management of chronic coronary syndromes)”.
C.R.
.